-
Featured Authors
Inside BIO
- Big Red Biotech blog
- Biocentury
- BiotechBlog
- Bruce Booth
- Fierce Biotech
- Get the Facts from Farmer Gene
- GMO Pundit
- Harvest Public Media
- In Vivo Blog
- Industrial Biotechnology and Climate Change
- Partnership to Improve Patient Care
- Patent Baristas
- Patently BIOtech
- Pharmalot
- Xconomy – Life Sciences
- YouTube – The BIOchannel
Category Archives: Inside BIO Industry Analysis
Sector Performance Since the 2007 Market Peak
How does the biotech sector performance rank against the 10 S&P sectors since the S&P500 peak back on October 9th, 2007? As of January 6th, 2010, the Nasdaq Biotech Index (NBI) outperformed all 10 sectors, including the overall healthcare sector and the other traditionally defensive sectors: utilities and consumer staples. The AMEX Biotech Index (BTK) had some unique events in 2009 that helped it not only outperform every sector, but remain in double digit positive Read More >
Risk/Reward Favored Small & Micro Caps in 2009
For US biotechs in 2009, the smaller the company’s market capitalization, the higher the return…
2009 – A Big Year for the BTK
The Amex Biotech Index, the BTK, outpaced its peer, the Nasdaq Biotech Index, by 29% and was 22% above the SP500. Most of this can be attributed to 3rd quarter performance when Human Genome Sciences (HGSI) released P3 data for their antibody drug for Lupus. HGSI gained 555% in 3Q09, and the impact on the 20 company BTK can be seen in the lower bar chart. * *It should be noted that both major Read More >
Small Biotechs Spending Less
The median and mean operational cash spending for small public US biotechs (less than 250 employees) is down 37% and 42% respectively, since the 1st Quarter of 2008. Company cut backs have shown up in the lay-off numbers as well as in the number of drug development projects put on hold. These quarterly numbers give a sense of the direction. For a look at the annual data, here is how spending breaks down for the Read More >
1 in 4 Biotechs Above 100% – Waterfall Chart YTD
Year to date, 27% of biotech stocks have doubled in price. 65% are in positive territory in 2009, a strong contrast to the YTD data last year:
